+41 91 682 20 40 info@elixi-int.com

Vyxeos (daunorubicin and cytarabine) Receives Marketing Authorisation in the European Union for Treatment of Certain Types of High-Risk Acute Myeloid Leukaemia

Jazz Pharmaceuticals plc has announced that the European Commission approved Vyxeos 44 mg/100 mg powder for concentrate for solution for infusion for the treatment of adults with newly diagnosed, therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC). Vyxeos is an advanced liposomal formulation…

Read More

Genentech Announces Submission of Supplemental New Drug Application for Venclexta (venetoclax) for People With Previously Untreated Acute Myeloid Leukemia who are Ineligible for Intensive Chemotherapy

Genentech has announced submission of a supplemental New Drug Application to the U.S. Food and Drug Administration (FDA) for Venclexta (venetoclax), in combination with a hypomethylating agent or in combination with low dose cytarabine (LDAC), for treatment of people with previously…

Read More